SinuSys Patency of Frontal Recess and Sphenoid Sinus Ostia Study
NCT ID: NCT02463279
Last Updated: 2016-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2015-04-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SinuSys Dilation System
Opening of previously constrained frontal recess and/or sphenoid sinus ostia via dilation procedure (sinuplasty)
Sinusys Dilation System
Dilation of frontal recess and/or sphenoid sinus ostia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sinusys Dilation System
Dilation of frontal recess and/or sphenoid sinus ostia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject in in need of frontal recess and/or sphenoid sinus dilation
Exclusion Criteria
* Previous treatment site intervention
* Cystic fibrosis, aspirin sensitivity, steroid dependent asthma, sinonasal tumors, allergic fungal sinusitis, ciliary dysfunction, atrophic nasal mucosa, excessive osteogenesis that might preclude dilation
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SinuSys Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerome Hester, MD
Role: STUDY_DIRECTOR
SinuSys Chief Medical Officer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Upland ENT
Upland, California, United States
Colorado ENT
Denver, Colorado, United States
St. Elizabeth Medical Center
Brighton, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNS-006
Identifier Type: -
Identifier Source: org_study_id